SAFETY ANALYSIS OF LEDIPASVIR/SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN, IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: ADVERSE EVENTS AND DRUG INTERACTIONS